Therapiealgorithmus zur Lipoproteinapherese und PCSK9-Inhibition bei schwerer Hypercholesterinämie oder isolierter Lipoprotein(a)-Hyperlipoproteinämie-Reference-Cited by-同舟云学术

Therapiealgorithmus zur Lipoproteinapherese und PCSK9-Inhibition bei schwerer Hypercholesterinämie oder isolierter Lipoprotein(a)-Hyperlipoproteinämie

Published:2016-04-27 Issue:5 Volume:57 Page:511-516
ISSN:0020-9554
Container-title:Der Internist
language:de
Short-container-title:Internist

Author:

Schettler V. J. J., ,Ringel J.,Jacob S.,Julius U.,Klingel R.,Heigl F.,Roeseler E.,Grützmacher P.,

Publisher

Springer Science and Business Media LLC

Subject

Internal Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00108-016-0043-9.pdf

Reference35 articles.

1. Hegele RA, Gidding SS, Ginsberg HN et al (2015) Nonstatin low-density lipoprotein-lowering therapy and cardiovascular risk reduction-statement from aTVB council. Arterioscler Thromb Vasc Biol 35:2269–2280

2. Calling S, Ji J, Sundquist J et al (2013) Shared and non-shared familial susceptibility of coronary heart disease, ischemic stroke, peripheral artery disease and aortic disease. Int J Cardiol 168:2844–2850

3. Cholesterol Treatment Trialists C, Fulcher J, O’Connell R et al (2015) Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 385:1397–1405

4. Bohula EA, Giugliano RP, Cannon CP et al (2015) Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of Ezetimibe to Simvastatin and associated with better outcomes in IMPROVE-IT. Circulation 132:1224–1233

5. Ray KK, Kastelein JJ, Boekholdt SM et al (2014) The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J 35:960–968